Showing 2071-2080 of 5771 results for "".
- 4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of 4D-125 for the Treatment of XLRPhttps://modernod.com/news/4d-molecular-therapeutics-announces-first-patient-dosed-in-phase-1-2-trial-of-4d-125-for-the-treatment-of-x-linked-retinitis-pigmentosa/2478179/4D Molecular Therapeutics (4DMT) announced that the first patient has been dosed in the phase 1/2 clinical trial of 4D-125 for X-linked retinitis pigmentosa (XLRP). 4D-125 is an AAV gene therapy with an optimized and proprietary vector designed to deliver a functional copy of the RPGR gene to pho
- Eyenovia and Arctic Vision Announce License Agreement to Develop and Commercialize Products in Greater China and South Koreahttps://modernod.com/news/eyenovia-and-arctic-vision-announce-license-agreement-to-develop-and-commercialize-products-in-greater-china-and-south-korea/2478143/Eyenovia and Arctic Vision announced that they have entered into an exclusive license agreement for Arctic Vision to develop and commercialize MicroPine for the treatment of progressive myopia and MicroLine for the treatment of presbyopia in Greater China (mainland China, Hong Kong, Macau and Tai
- Clearside Biomedical Announces FDA Acceptance of Investigational NDA for CLS-AX Administered in Suprachoroidal Spacehttps://modernod.com/news/clearside-biomedical-announces-fda-acceptance-of-investigational-nda-for-cls-ax-administered-in-suprachoroidal-space/2478140/Clearside Biomedical announced that the FDA has accepted its investigational new drug (IND) application for CLS-AX (axitinib injectable suspension), enabling initiation of a phase 1/2a clinical trial of CLS-AX in wet age-related macular degeneration (AMD) patients by the end of 20
- Sight Sciences Announces First Patients Enrolled in ORION Clinical Trial of the OMNI Surgical Systemhttps://modernod.com/news/sight-sciences-announces-first-patients-enrolled-in-orion-clinical-trial-of-the-omni-surgical-system/2478138/Sight Sciences announced the enrollment of the first patients in the ORION clinical study. The purpose of the study is to build upon the body of clinical evidence and commercial use of the OMNI Surgical System in pseudophakic eyes by providing ophthalmic surgeons with prospective, multicenter cli
- Gyroscope Announces Appointment of Leaders in Retinal Disease, Gene Therapy and the Complement System to Advisory Boardshttps://modernod.com/news/gyroscope-announces-appointment-of-leaders-in-retinal-disease-gene-therapy-and-the-complement-system-to-advisory-boards/2478130/Gyroscope Therapeutics announced the appointment of leading experts in retinal disease, gene therapy, and the complement system to its Clinical and Scientific advisory boards. The newly appointed boards will help guide the development of the company’s lead investigational gene therapy, GT00
- Vision Expo Announces Virtual EYE2EYE Series Topics for Augusthttps://modernod.com/news/vision-expo-announces-virtual-eye2eye-series-topics-for-august/2478126/Vision Expo announced the upcoming Virtual EYE2EYE Series topics scheduled for August. August 5: SHE Did That! Dr. Danielle Richardson, Optometrist and Founder at Fierce Clarity, will explore the passionate pursuits of Black women in eyecare and their entrepreneurshi
- Eyenuk Announces FDA Clearance for EyeArt Autonomous AI System for Diabetic Retinopathy Screeninghttps://modernod.com/news/eyenuk-announces-fda-clearance-for-eyeart-autonomous-ai-system-for-diabetic-retinopathy-screening/2478123/Eyenuk announced it has received 510(k) clearance by the FDA to market its EyeArt autonomous AI System for diabetic retinopathy. EyeArt is indicated for use by health care providers to automatically detect more than mild diabetic retinopathy (mtmDR) and vision-threatening diabetic retinopa
- EyePoint Pharmaceuticals and ImprimisRx Announce U.S. Commercial Alliance for Dexycuhttps://modernod.com/news/eyepoint-pharmaceuticals-and-imprimisrx-announce-u-s-commercial-alliance-for-dexycu/2478119/EyePoint Pharmaceuticals and ImprimisRx announced the signing of a commercial alliance for the joint promotion of Dexycu (dexamethasone intraocular suspension) 9% for the treatment of postoperative inflammation following ocular surgery in the United States.
- 4D Molecular Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of 4D-110 by Intravitreal Injection for the Treatment of Choroideremiahttps://modernod.com/news/4d-molecular-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-4d-110-by-intravitreal-injection-for-the-treatment-of-choroideremia/2478092/4D Molecular Therapeutics (4DMT) announced that the first patient has been dosed in the phase 1 clinical trial of 4D-110, a Roche-licensed product candidate, delivered by a single intravitreal injection for Choroideremia. Choroideremia is a blinding and currently untreatable X-linked inher
- AcuFocus Announces Extended Diopter Range for the IC-8 Small Aperture IOLhttps://modernod.com/news/acufocus-announces-extended-diopter-range-for-the-ic-8-small-aperture-iol/2478087/AcuFocus announced that the IC-8 small aperture IOL power range now extends from +10.0 D to +30.0 D (0.50 D steps), offering eye care physicians the opportunity to provide more patients an uninterrupted extended range